Clinical Trials at Oregon Health and Science University
As of August 2026, 197 paid clinical trials are recruiting at Oregon Health and Science University, located at 3633 SE 35TH PL, ATTN: LIZ STEVENSON, PORTLAND, OR 97202-3365, phone (503) 494-4222 in Portland, Oregon. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Endometrial Cancer and Breast Cancer. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Portland
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease
200 clinical trials at Oregon Health and Science University
·Clear filters·A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
A Study of ASP3082 in Adults With Advanced Solid Tumors
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort B: Paridiprubart
JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort A: Vilobelimab
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy))
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
Common conditions studied in Portland
- Acute Myeloid Leukemia (18 active studies)
- Endometrial Cancer (17 active studies)
- Breast Cancer (16 active studies)
- Heart Failure (14 active studies)
- Ovarian Cancer (14 active studies)
- Advanced Solid Tumor (11 active studies)
Leading research sponsors in Portland
- Oregon Health and Science University
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
- AstraZeneca
- VA Office of Research and Development
Frequently asked questions
How many paid clinical trials are currently recruiting in Portland?
There are approximately 1,000 recruiting clinical trials in Portland, Oregon listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Portland pay participants?
Most recruiting trials in Portland compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Portland?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Portland?
The most common conditions under active study in Portland include Acute Myeloid Leukemia (18), Endometrial Cancer (17), Breast Cancer (16), Heart Failure (14), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Portland?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Portland on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Portland?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Portland?
Recruiting research sites in Portland include Oregon Health and Science University, Oregon Health & Science University, Providence Portland Medical Center, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Portland right now?
The largest active categories in Portland are Cancer & tumors (356), Neurology & pain (66), Cardiovascular (46). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Oregon Health and Science University?
Oregon Health and Science University is located at 3633 SE 35TH PL, ATTN: LIZ STEVENSON, PORTLAND, OR 97202-3365. Use the Google Maps link in the intro above to get directions.
How do I contact Oregon Health and Science University?
You can reach Oregon Health and Science University by phone at (503) 494-4222. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.